- Home
- ABVC vs IGC Comparison
ABVC vs IGC Comparison
Compare ABVC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- IGC
- Stock Information
- Founded
- ABVC 2015
- IGC 2005
- Country
- ABVC United States
- IGC United States
- Employees
- ABVC N/A
- IGC N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- IGC Health Care
- Exchange
- ABVC Nasdaq
- IGC Nasdaq
- Market Cap
- ABVC 22.1M
- IGC 20.2M
- IPO Year
- ABVC N/A
- IGC N/A
- Fundamental
- Price
- ABVC $4.35
- IGC $0.33
- Analyst Decision
- ABVC
- IGC Strong Buy
- Analyst Count
- ABVC 0
- IGC 2
- Target Price
- ABVC N/A
- IGC $3.88
- AVG Volume (30 Days)
- ABVC 571.3K
- IGC 270.9K
- Earning Date
- ABVC 08-13-2025
- IGC 08-07-2025
- Dividend Yield
- ABVC N/A
- IGC N/A
- EPS Growth
- ABVC N/A
- IGC N/A
- EPS
- ABVC N/A
- IGC N/A
- Revenue
- ABVC $508,383.00
- IGC $1,271,000.00
- Revenue This Year
- ABVC $735.18
- IGC $15.26
- Revenue Next Year
- ABVC N/A
- IGC $3.41
- P/E Ratio
- ABVC N/A
- IGC N/A
- Revenue Growth
- ABVC 1904.43
- IGC N/A
- 52 Week Low
- ABVC $0.40
- IGC $0.25
- 52 Week High
- ABVC $5.48
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- ABVC 74.35
- IGC 63.68
- Support Level
- ABVC $2.16
- IGC $0.30
- Resistance Level
- ABVC $5.48
- IGC $0.32
- Average True Range (ATR)
- ABVC 0.43
- IGC 0.01
- MACD
- ABVC 0.23
- IGC 0.00
- Stochastic Oscillator
- ABVC 64.84
- IGC 100.00
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.